After the PCAC votes: what FDA reclassification actually looks like in practice

The forum framing collapses everything that happens after July 24 into a single event. PCAC voted yes arrives in the same sentence as now you can get a prescription. They are not the same sentence. There is a long, formal, public process between them, and it is where the actual access changes.

This is the part of the picture worth understanding before the vote, so that when the result lands you can read what it does and what it doesn’t.

A PCAC vote is a recommendation. Then the FDA writes the rule.

PCAC is an advisory committee. That word does work the forum coverage will skip. The committee meets, hears testimony, deliberates, and votes — and the vote is a recommendation to the FDA. It is not itself a regulation. It is not itself a permission to dispense. It is the formal data point the FDA is required to take into account when it next writes the rule for the Section 503A bulk drug substances list.

That distinction sets the pace of everything that follows. The vote happens on a known date in a public meeting. The rule that follows the vote happens on the FDA’s timeline, through formal rulemaking, with its own public comment period and its own publication schedule. The committee can vote on Friday. The rule the FDA writes from that vote will arrive months later.

In rough shape, the path from a favourable PCAC vote to a prescription you can actually fill goes through four stages.

The vote. Recorded on the day, published in the meeting summary. The committee makes a recommendation by named member vote. Splits are recorded.

The proposed rule. The FDA publishes a notice of proposed rulemaking in the Federal Register that includes the substance on the 503A bulks list — or doesn’t — for the indication the committee evaluated. The proposed rule explains the agency’s reasoning. A public comment period opens, typically thirty to ninety days.

The final rule. After the comment period closes, the FDA reviews comments and publishes the final rule. This is the document that legally changes the 503A list. Until it publishes, nothing has changed for compounding pharmacies.

Compounding begins. Once the final rule is in effect, US-licensed compounding pharmacies — both Section 503A traditional pharmacies and Section 503B outsourcing facilities — can use the substance for the indication on the list, in compounded prescriptions written for named patients.

Each of those steps takes weeks at minimum and months in practice. There is no version where the July vote produces a fillable prescription in August.

What the indication on the rule actually does

The single most consequential thing about the rule the FDA writes is the indication it attaches. PCAC votes on a substance for a specific use. The rulemaking that follows ties the compounding allowance to that use.

For BPC-157 the indication on the docket is ulcerative colitis. If the committee recommends inclusion and the FDA writes that into the 503A bulks list, what a US compounding pharmacy gains is the legal allowance to compound BPC-157 for ulcerative colitis prescriptions. A doctor writing a prescription for BPC-157 for a torn shoulder is then writing an off-label use of a compounded drug — a position that is not illegal but that puts the prescribing decision squarely on the supervising physician, with the disclosure and informed-consent conversations that go with it.

The same shape repeats across the docket. TB-500 for wound healing, MOTs-C for obesity and osteoporosis, DSIP for opioid withdrawal and insomnia, Semax for cerebral ischemia and migraine, Epitalon for insomnia. The compounding-pathway floor is at the indication on the rule. Everything outside that floor is the prescribing physician’s clinical judgement and the patient’s informed consent — a more careful conversation, but a real one, in a way that vials from a research-chemical website never were.

What an unfavourable vote does

An unfavourable PCAC vote does not by itself ban a compound. What it does is signal to the FDA that the recommended position is exclusion from the 503A bulks list, and the agency’s subsequent rulemaking will almost certainly reflect that. The compound is then not legally compoundable for the reviewed indication. The off-label supply chain — research-chemical vendors, no prescription, no supervising physician — remains the only one available for that substance.

This is the present-tense situation for the four peptides that already had their PCAC review in 2024 and lost: CJC-1295, ipamorelin, AOD-9604, and Thymosin alpha-1. None of them have a US compounding pathway today, and none of them are getting another PCAC review in 2026 or 2027. Whatever supply chain they currently sit in is the supply chain they will sit in until something material changes — a new application, a different regulatory route, or a marketed-drug approval that none of these compounds are close to. The forum framing treating them as still in play does not match the regulatory record.

What changes for patients when the final rule publishes

Three things, concretely.

A US-licensed physician can write a prescription for the named indication, knowing the compound is on the 503A list and a US pharmacy can fill it. The conversation moves out of can I get this somewhere and into should I take this for this indication.

A US-licensed compounding pharmacy can source the bulk substance through legitimate channels with documented identity, purity, and potency testing — the same quality framework that applies to every other compounded drug. Whether 503A traditional pharmacies, 503B outsourcing facilities, or both will engage with each compound is a market question and a per-pharmacy decision, but the legal allowance is in place.

A patient receives a labelled vial with a known concentration, sourced from a pharmacy operating under federal and state inspection. The compounded product has not been through FDA approval as a marketed drug. It is a compounded prescription with a known floor under it.

What does not change, in the short term, is the breadth of the indication. The 503A bulks list does not authorise marketing for indications beyond the one on the list. Off-label prescribing remains a physician decision under the same standards that govern off-label prescribing for any other compounded drug. The supplement-market pitch and the clinical use case are still separate conversations, even after the rule publishes.

How long, roughly

Federal rulemaking on the 503A bulks list has historically run anywhere from several months to over a year between a PCAC vote and a final rule. There is no statutory deadline that compresses the timeline for the July or February meetings. A best-case path from a favourable July vote to a final rule in effect is probably late 2026 to mid-2027. A typical path is longer. A contested path, with substantial comment volume or revisions to the proposed rule, can stretch into 2028.

The honest read is that whatever the committee recommends in July, the access change that follows is a 2027 conversation at the earliest for most of the seven compounds, and a 2028 conversation for the five in the second wave. The vote is the directional signal. The rule is the access event. Conflating them is how the timeline gets misrepresented.

What this means while you wait

Right now the only supply chain for the twelve peptides under PCAC review across both waves runs through research-chemical vendors. Not for human consumption labels. No third-party testing of identity, purity, or potency. No prescription. No supervising physician. No recourse if a vial turns up under-dosed, contaminated, or carrying the wrong compound entirely. The PCAC process — vote, proposed rule, final rule, compounding access — is the legal route from that supply chain to a different one. None of it is fast.

What you can do in the interim is choose your sources carefully on the science, watch the regulatory record itself rather than the forum framing of it, and decide whether the wait for a legitimate pathway is worth a sample of the off-label market in the meantime. Those are individual decisions with individual stakes.

When the legitimate version exists

The access event that matters for any peptide on the July docket is the final rule the FDA writes after the vote — not the vote itself. Wolverine Health is the clinical operation being built to dispense each compound the moment that final rule publishes for it: physician-supervised prescriptions, US-licensed compounding pharmacies, third-party-tested batches. The vote sets direction. The rule sets access. We move on the rule.

Join the waitlist to be told the moment the version of a peptide you are tracking is something a US pharmacy can actually dispense, on a US prescription, with your name on the label.